Adbry® (tralokinumab-ldrm) – Expanded indication
December 14, 2023 - The FDA approved Leo Pharma’s Adbry (tralokinumab-ldrm), for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Adbry can be used with or without topical corticosteroids.
Top